title: Systemic lupus erythematosus following rituximab treatment for non-Hodgkin lymphoma.
authors.affiliation: 1st University Department of Dermatology/Venereology, Andreas Syggros Hospital, University of Athens, Athens, Greece.
authors.forename: Efthymia
authors.initials: E
authors.lastname: Soura
authors.affiliation: 1st University Department of Dermatology/Venereology, Andreas Syggros Hospital, University of Athens, Athens, Greece.
authors.forename: Georgia
authors.initials: G
authors.lastname: Avgerinou
authors.affiliation: 1st University Department of Dermatology/Venereology, Andreas Syggros Hospital, University of Athens, Athens, Greece.
authors.forename: Marina
authors.initials: M
authors.lastname: Papoutsaki
authors.affiliation: 1st University Department of Dermatology/Venereology, Andreas Syggros Hospital, University of Athens, Athens, Greece.
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Stavropoulos
authors.affiliation: 1st University Department of Dermatology/Venereology, Andreas Syggros Hospital, University of Athens, Athens, Greece.
authors.forename: Christina
authors.initials: C
authors.lastname: Antoniou
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000175:diagnosis* / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D000069283:Rituximab / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000069283:Rituximab